← Back to Analyst Consensus 
ZURA Buy
Zura Bio Ltd
Current Price —
Implied Upside —
Analysts 14
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 18, 2026 (23 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 12, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Aug 12, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jul 8, 2026 | William Blair | initiate | — → Outperform | — | 48% |
| Jul 1, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Mar 23, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Mar 20, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Feb 9, 2026 | Wedbush | initiate | — → Outperform | $15 | 58% |
| Nov 14, 2025 | Chardan Capital | maintain | Buy → Buy | $10 | 47% |
| Nov 13, 2025 | Clear Street | initiate | — → Buy | $18 | 48% |
| Sep 30, 2025 | Chardan Capital | maintain | Buy → Buy | $10 | 47% |
| Aug 19, 2025 | HC Wainwright & Co. | maintain | Neutral → Neutral | $2 | 44% |
| Aug 15, 2025 | Oppenheimer | maintain | Outperform → Outperform | $16 | 52% |
| Aug 15, 2025 | Chardan Capital | maintain | Buy → Buy | $10 | 47% |
| May 9, 2025 | Oppenheimer | maintain | Outperform → Outperform | $17 | 52% |
| Apr 3, 2025 | HC Wainwright & Co. | maintain | Neutral → Neutral | $3 | 44% |
| Mar 26, 2025 | Oppenheimer | maintain | Outperform → Outperform | $19 | 52% |
| Mar 26, 2025 | Guggenheim | reiterate | Buy → Buy | $15 | 52% |
| Mar 26, 2025 | Chardan Capital | maintain | Buy → Buy | $10 | 47% |
| Dec 24, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $5 | 44% |
| Dec 11, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $0 | 50% |
| Nov 18, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $5 | 44% |
| Nov 11, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $5 | 44% |
| Nov 8, 2024 | Chardan Capital | maintain | Buy → Buy | $12 | 47% |
| Nov 4, 2024 | Leerink Partners | initiate | — → Outperform | $15 | 51% |
| Oct 21, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $5 | 44% |
| Oct 18, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Sep 19, 2024 | Piper Sandler | maintain | Overweight → Overweight | $26 | 54% |
| Sep 5, 2024 | HC Wainwright & Co. | initiate | — → Neutral | $5 | 44% |
| Aug 15, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Jun 17, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Jun 12, 2024 | Cantor Fitzgerald | initiate | — → Overweight | $0 | 50% |
| May 10, 2024 | Oppenheimer | maintain | Outperform → Outperform | $21 | 52% |
| May 3, 2024 | Piper Sandler | initiate | — → Overweight | $26 | 54% |
| Apr 1, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $16 | 52% |
| Oct 10, 2023 | Ladenburg Thalmann | initiate | — → Buy | $10 | 45% |
| Aug 25, 2023 | Oppenheimer | initiate | — → Outperform | $17 | 52% |
| Aug 15, 2023 | Raymond James | maintain | Strong Buy → Strong Buy | $22 | 54% |
| Jun 22, 2023 | Guggenheim | initiate | — → Buy | $20 | 52% |
| Jun 14, 2023 | Chardan Capital | initiate | — → Buy | $14 | 47% |
| May 24, 2023 | Raymond James | initiate | — → Strong Buy | $20 | 54% |
Price Target Trend
Apr 2, 2026 Oct 26, 2026
EPS Estimates
0y —
+1y —
+1q —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days